Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olvi-Vec in Peritoneal Carcinomatosis
NCT01443260Phase 2Completed
- Sponsor
- Genelux Corporation
- Start
- Feb 2012
- Primary completion
- Sep 2014
- Modality
- Prophylactic Vaccines, Oncolytic Viruses, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of olvimulogene nanivacirepvec in peritoneal carcinomatosis (PC), sponsored by Genelux Corporation. Started Feb 2012; status: completed.
02
Drugs
olvimulogene nanivacirepvec
03
Conditions
peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NCT01443260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01443260.